Exploration of aminopeptidase N as new biomarker for early diagnosis of thyroid cancer

Biosens Bioelectron. 2024 Jan 15:244:115808. doi: 10.1016/j.bios.2023.115808. Epub 2023 Nov 2.

Abstract

False-positive diagnosis and overdiagnosis are ongoing issues in clinical diagnosis of thyroid cancer. Identifying new disease markers is crucial for early diagnosis and improved treatment. Aminopeptidase N (APN) is a promising biomarker for cancer diagnosis due to its critical roles in tumor invasion, metastasis, angiogenesis, and other processes. However, its potential as biomarker for thyroid cancer diagnosis needs further investigation. This study developed an ultra-sensitive near-infrared fluorescence probe, LAN-apn, to investigate the expression level of APN in thyroid cancer and evaluate its potential as biomarker of thyroid cancer. LAN-apn could accurately and sensitively determine APN through fluorescence method (DL = 0.069 ng/mL) and colorimetric method (DL = 4.5 ng/mL). In addition, LAN-apn allowed for successful fluorescence imaging of APN in thyroid cancer cells and thyroid cancer tumors both in vivo and in vitro, and confirmed that APN was significantly upregulated in thyroid cancer. Therefore, APN may become a new biomarker for thyroid cancer diagnosis, and LAN-apn could be used as a new imaging tool for the study of APN-thyroid cancer relationship and the early diagnosis of thyroid cancer.

Keywords: Aminopeptidase N; Fluorescence probe; Imaging in cells; Imaging in vivo; Thyroid cancer.

MeSH terms

  • Biosensing Techniques*
  • CD13 Antigens / metabolism
  • Early Detection of Cancer
  • Humans
  • Thyroid Neoplasms* / diagnosis

Substances

  • CD13 Antigens